Aurinia Pharmaceuticals (AUPH) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Aurinia Pharmaceuticals (AUPH) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 43.3% versus a loss of 14.4%. Over five years, VRDN leads with a +9.3% price change compared with -19.1% for AUPH. Aurinia Pharmaceuticals is the larger company by market cap ($2.22 billion vs $2.11 billion), about 1.0 times the size, while Viridian Therapeutics is growing revenue faster (+23359.9% vs +20.4%).
Aurinia Pharmaceuticals converts more of its revenue into profit, with a net margin of 101.5% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUPH | VRDN |
|---|---|---|
| Share price | $16.65 | $18.66 |
| Market cap | $2.22B | $2.11B |
| 1-day change | +2.65% | +1.74% |
| YTD return | +4.39% | -40.04% |
| 1-year return | +43.29% | -14.44% |
| 5-year return | -19.06% | +9.31% |
| P/E ratio (TTM) | 7.12 | — |
| Forward P/E | 15.61 | — |
| EPS (TTM) | $2.34 | $-3.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $283.06M | $70.85M |
| Revenue growth (YoY) | +20.38% | +23359.93% |
| Net income (latest FY) | $287.20M | $-342.60M |
| Gross margin | 88.46% | — |
| Operating margin | 37.06% | -512.91% |
| Net margin | 101.47% | -483.57% |
| 52-week high | $19.25 | $34.29 |
| 52-week low | $10.90 | $13.18 |
| Distance from 52-week high | -13.51% | -45.58% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +7.27% | +96.95% |
| Average volume | 977.05K | 1.71M |
| Shares outstanding | 133.05M | 113.29M |
| Employees | 128 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUPH has outperformed VRDN by 57.7 percentage points over the past year.
- Aurinia Pharmaceuticals is more profitable, keeping 101.5 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +20.38%).
About Aurinia Pharmaceuticals
AUPH stock →Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
AUPH vs VRDN FAQ
Which is bigger, Aurinia Pharmaceuticals or Viridian Therapeutics?
Aurinia Pharmaceuticals (AUPH) is larger, with a market capitalization of $2.22B compared with $2.11B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, AUPH or VRDN?
AUPH returned +43.29% over the past 12 months, compared with -14.44% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Aurinia Pharmaceuticals and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.